Follow us on Social & Subscribe to our newsletter to learn more about EDCC!

ViewRay Headquarters Announcement

Viewray headquarters


In mid-2019, ViewRay established an office in Denver starting with fewer than ten teammates. ViewRay’s presence in Denver has now grown to over 50 teammates with the expansion of the company’s international marketing, finance, and legal teams. ViewRay is one of the fastest growing companies in the med-tech sector with plans for considerable growth in Denver.

ViewRay expects to continue expanding its Denver team with additional high-paying roles in product development, manufacturing, and quality and, in 2023, the company plans to add another building focused on development, manufacturing, and physician training.

Colorado is home to a robust bioscience industry making the Mile High City an ideal location to do business and introduce clinicians to life saving radiation therapy. According to Colorado Bioscience Association:

  • Colorado is home to 720 life sciences companies and organizations.
  • More than 32,000 people are directly employed by the bioscience industry, averaging a $96,000 annual salary.
  • Metro Denver has the 8th largest medical device sector across the U.S.

Over the past 20 years, ViewRay’s CEO, Scott Drake, and the ViewRay executive team, have created over 3,000 med tech jobs in Colorado.

“We are proud to welcome ViewRay headquarters to Colorado, an exciting move that brings good-paying jobs to Coloradans,” said Gov. Polis. “As we continue to save people money and support small businesses, Colorado remains the best place to live, work, and do business.”

“ViewRay relocating to Denver will create more opportunity for our tech-sector talent base and continue to elevate our community as a center for healthcare innovation. Guided by the values of a healthy community and healthy community-engagement, we couldn’t be prouder that they’ve chosen our great city to realize their ambitious mission to improve cancer treatment technology and ultimately, save thousands of lives,” Denver Mayor Michael B. Hancock said.

“ViewRay is excited that Colorado will be the international headquarters for this innovative cancer therapy. The state is a magnet for talented professionals and academics in our field and is fast becoming a center of the international bioscience industry,” said Scott Drake President and CEO of ViewRay. “We look forward to growing as a company, but more importantly, we are committed to conquering cancer by re-envisioning radiation therapy because lives depend on it. Patients deserve short-course non-invasive therapy with fewer side effects and better quality of life, whether they face complex or more common forms of cancer. ViewRay is committed to delivering that to every patient who requires treatment.”

About MRIdian
Radiation therapy treatment works by delivering radiation to tumor sites. However, clinicians must limit the amount of radiation given to the tumor to preserve surrounding healthy tissue and organs. With conventional technology, clinicians do so by spreading the amount of radiation given over several weeks bringing the patient in for 20-30-40 treatments. In short, they are confronted with a trade-off between safety and effectiveness; as well as quality of life based on treatment schedule.

The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs-at-risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.

Nearly 25,000 patients have been treated with MRIdian. Currently, 53 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. For a list of treatment centers, please visit:

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.